GSK plc 6-K, filed Jun 22, 2023
GSK plc (GSK)
6-K
2023-06-22
For: 2023-06-22
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on June 22, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 22 June 2023, London UK
US Centers for Disease Control and
Prevention's Advisory Committee on Immunization Practices votes to
recommend Arexvy for the prevention of RSV disease in adults
aged 60 and older with shared clinical decision
making
● Launch is planned in the US before the 2023 RSV
season
●
Committee recommendations mean
over 55 million older adults in the US could have access to RSV
vaccination for the first time1
●
RSV
causes approximately 177,000 hospitalisations and 14,000 deaths in
adults aged 65 years and older in the US each
year2,3,4
GSK plc (LSE/NYSE: GSK) today announced that the US Centers for
Disease Control and Prevention's (CDC) Advisory Committee on
Immunization Practices (ACIP) voted in favour of recommending the
use of Arexvy (respiratory syncytial virus vaccine,
adjuvanted) in adults aged 60 and older using shared clinical
decision making. Shared clinical decision making empowers patients
in consultation with their healthcare providers to determine
whether RSV vaccination is appropriate for
them.
There are an estimated 55.8 million people aged 65 and older in the
US1 who
are at increased risk of RSV, a
common, contagious virus that can lead to serious respiratory
illness.2 RSV
causes approximately 177,000 hospitalisations and an estimated
14,000 deaths in this age group in the US each
year.2.3,4 For
adults 60 and older, data suggest an increased risk for severe RSV
infection that can lead to hospitalisation.5,6 Older
adults, including those with underlying medical conditions*, such
as chronic heart disease, chronic lung disease or diabetes, are at
high risk of severe RSV illness and account for the majority of RSV
hospitalisations.5
Tony Wood, Chief Scientific Officer, GSK, said: "GSK's successful development of an
RSV vaccine to help protect older adults from RSV lower respiratory
tract disease (LRTD) represents a major scientific advance,
resulting from years of collaboration across academia, industry,
and research centres. We are grateful to the ACIP and CDC for
recognising the potential of Arexvy and look forward to partnering with public
health officials, healthcare professionals and payers to make it
available for eligible older adults in the US before this year's
RSV season begins."
In making its recommendation, the ACIP considered evidence from the
comprehensive data package supporting the vaccine, including in
older adults with underlying medical conditions. This includes
results from the first season of the pivotal AReSVi-006
(Adult Respiratory Syncytial Virus) phase III trial,
published in the New
England Journal of Medicine in
February 2023.7 During
the ACIP meeting, GSK also presented data from the Northern
Hemisphere second season of the trial, which remains ongoing to
explore the effect of the vaccine over multiple seasons and the
optimal timing for potential revaccination.
These data will be submitted to the US Food and Drug Administration
(FDA) for review.
The ACIP recommendations will be forwarded to the director of the
CDC and the US Department of Health and Human Services for review
and approval. Once approved, the final recommendations will be
published in a future Morbidity and Mortality Weekly Report (MMWR)
to advise healthcare providers on appropriate use of the
vaccine.
* According to the CDC, adults aged 60 and older at even greater
risk of severe respiratory illness include those with chronic lung
diseases, chronic cardiovascular diseases, immune-compromise,
hematologic disorders, neurologic disorders, endocrine disorders,
kidney and liver disorders and other
factors 8
About Arexvy (respiratory syncytial virus vaccine,
adjuvanted)
Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein
F stabilised in the prefusion conformation (RSVPreF3). This antigen
is combined with GSK's proprietary AS01E adjuvant.7
The vaccine was approved by the US FDA on 3 May 2023 for the
prevention of LRTD caused by RSV in individuals 60 years of age and
older.9
In
clinical trials, the vaccine was generally well tolerated. The most
frequently observed solicited adverse events were injection site
pain, fatigue, myalgia, headache, and arthralgia. These were
generally mild to moderate and transient.7
In June 2023, the European Commission authorised the vaccine for active immunisation for the
prevention of LRTD caused by RSV in adults aged 60 years and
older.10 Regulatory
reviews in Japan and other counties are
ongoing.
The vaccine is not approved anywhere else in the world. The
proposed trade name remains subject to regulatory approval in other
markets.
The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON
adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of
Agenus Inc.
Please see the full US Prescribing
Information: https://www.fda.gov/media/167805/download
About RSV in older adults
RSV is a common contagious virus affecting the lungs and breathing
passages.3 Older
adults are at high risk for severe disease due in part to
age-related decline in immunity3,
and older adults with underlying conditions are at even greater
risk for severe disease.5 RSV
can exacerbate conditions, including chronic obstructive pulmonary
disease (COPD), asthma, and chronic heart failure and can lead to
severe outcomes, such as pneumonia, hospitalisation, and
death.2 Each
year, approximately 177,000 adults 65 years and older are
hospitalised in the US due to RSV; an estimated 14,000 cases result
in death.2,3,4 For
adults 60 and older, data suggest an increased risk for severe RSV
infection that can lead to hospitalisation.5,6 Adults
with underlying conditions are more likely to seek medical services
and have higher hospitalisation rates than adults without these
conditions.5
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7736 063933
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include but are not limited to those described under Item 3.D 'Risk
factors" in the company's Annual Report on Form 20-F for 2022,
GSK's Q1 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
1. United
States Census Bureau. The older population: 2020. Accessed May
2023. Available at:
https://www2.census.gov/library/publications/decennial/2020/census-briefs/c2020br-07.pdf
2. Centers
for Disease Control and Prevention. RSV in Older Adults and Adults
with Chronic Medical Conditions. Accessed May 2023. Available
at: www.cdc.gov/rsv/high-risk/older-adults.html
3. National Foundation for Infectious Diseases. Respiratory
Syncytial Virus. Accessed May 2023. Available
at: www.nfid.org/infectious-disease/rsv/
4. Falsey AR, et al. Respiratory syncytial virus infection in
elderly and high-risk adults. N Engl J Med 2005;
352:1749-1759.
5. Tseng HF, et al. Severe morbidity and short- and mid- to
long-term mortality in older adults hospitalized with respiratory
syncytial virus infection. J Infect Dis. 2020;222(8):1298-1310.
doi:10.1093/infdis/jiaa361.
6. Belongia EA, et al. Clinical features, severity, and incidence
of RSV illness during 12 consecutive seasons in a community cohort
of adults ≥60 years old. Open Forum Infect Dis.
2018;5(12):ofy316. doi:10.1093/ofid/ofy316.
7. Papi et al. Respiratory Syncytial Virus
Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023;
388:595-608.
8. CDC presentation. 21 June 2023. Available at:
www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/07-RSV-Adults-Britton-508.pdf
9. US FDA new release. Issued 3 May 2023. Available
at: www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine
10. European Medicines Agency. Recombinant respiratory syncytial
virus pre-fusion F protein, adjuvanted with AS01E. Available at:
www.ema.europa.eu/en/medicines/human/EPAR/arexvy#authorisation-details-section
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
22, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|